HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells

Journal of Neuroimmunology

Volumn 250, Issue 1-2, 2012, Pages 27-34

  Wolpert, Fabian ^a   Roth, Patrick ^a   Lamszus, Katrin ^b   Tabatabai, Ghazaleh ^a   Weller, Michael ^a   Eisele, Günter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Glioblastoma; HLA E; Immunotherapy; NK cell; Stem cell

Indexed keywords

CD133 ANTIGEN; GAMMA INTERFERON; HLA E ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; SMALL INTERFERING RNA;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CELL SURFACE; CONTROLLED STUDY; GENE SILENCING; GLIOBLASTOMA; GLIOMA INITIATING CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREGULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; FLOW CYTOMETRY; GLIOBLASTOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; NEOPLASTIC STEM CELLS; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84864839342     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.05.010     Document Type: Article

References (45)

1. Arlettaz L., Villard J., de Rham C., Degermann S., Chapuis B., Huard B., Roosnek E. Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR alphabeta lymphocytes. Eur. J. Immunol. 2004, 34:3456-3464.
2. Bar E.E., Lin A., Mahairaki V., Matsui W., Eberhart C.G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 2010, 177:1491-1502.
3. Beier C.P., Beier D. CD133 negative cancer stem cells in glioblastoma. Front. Biosci. (Elite Ed.) 2011, 3:701-710.
4. Bertone S., Schiavetti F., Bellomo R., Vitale C., Ponte M., Moretta L., Mingari M.C. Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur. J. Immunol. 1999, 29:23-29.
5. Bianchini M., Levy E., Zucchini C., Pinski V., Macagno C., De Sanctis P., Valvassori L., Carinci P., Mordoh J. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int. J. Oncol. 2006, 29:83-94.
6. Castriconi R., Daga A., Dondero A., Zona G., Poliani P.L., Melotti A., Griffero F., Marubbi D., Spaziante R., Bellora F., Moretta L., Moretta A., Corte G., Bottino C. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 2009, 182:3530-3539.
7. de Kruijf E.M., Sajet A., van Nes J.G., Natanov R., Putter H., Smit V.T., Liefers G.J., van den Elsen P.J., van de Velde C.J., Kuppen P.J. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J. Immunol. 2010, 185:7452-7459.
8. Derre L., Corvaisier M., Charreau B., Moreau A., Godefroy E., Moreau-Aubry A., Jotereau F., Gervois N. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J. Immunol. 2006, 177:3100-3107.
9. Di Tomaso T., Mazzoleni S., Wang E., Sovena G., Clavenna D., Franzin A., Mortini P., Ferrone S., Doglioni C., Marincola F.M., Galli R., Parmiani G., Maccalli C. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 2010, 16:800-813.
10. Dietrich P.Y., Dutoit V., Tran Thang N.N., Walker P.R. T-cell immunotherapy for malignant glioma: toward a combined approach. Curr. Opin. Oncol. 2011, 22:604-610.
11. Eisele G., Wischhusen J., Mittelbronn M., Meyermann R., Waldhauer I., Steinle A., Weller M., Friese M.A. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006, 129:2416-2425.
12. Facoetti A., Nano R., Zelini P., Morbini P., Benericetti E., Ceroni M., Campoli M., Ferrone S. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin. Cancer Res. 2005, 11:8304-8311.
13. Friese M.A., Platten M., Lutz S.Z., Naumann U., Aulwurm S., Bischof F., Buhring H.J., Dichgans J., Rammensee H.G., Steinle A., Weller M. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003, 63:8996-9006.
14. Friese M.A., Steinle A., Weller M. The innate immune response in the central nervous system and its role in glioma immune surveillance. Onkologie 2004, 27:487-491.
15. Gooden M., Lampen M., Jordanova E.S., Leffers N., Trimbos J.B., van der Burg S.H., Nijman H., van Hall T. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8 T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10656-10661.
16. Griguer C.E., Oliva C.R., Gobin E., Marcorelles P., Benos D.J., Lancaster J.R., Gillespie G.Y. CD133 is a marker of bioenergetic stress in human glioma. PLoS One 2008, 3:e3655.
17. Gunther H.S., Schmidt N.O., Phillips H.S., Kemming D., Kharbanda S., Soriano R., Modrusan Z., Meissner H., Westphal M., Lamszus K. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008, 27:2897-2909.
18. Han S.J., Ahn B.J., Waldron J.S., Yang I., Fang S., Crane C.A., Pieper R.O., Parsa A.T. Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport 2009, 20:1597-1602.
19. Haque A., Banik N.L., Ray S.K. Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma. Neurochem. Res. 2007, 32:2203-2209.
20. Heimberger A.B., Sampson J.H. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. Neuro Oncol. 2011, 13:3-13.
21. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15178-15183.
22. Ieta K., Tanaka F., Haraguchi N., Kita Y., Sakashita H., Mimori K., Matsumoto T., Inoue H., Kuwano H., Mori M. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann. Surg. Oncol. 2008, 15:638-648.
23. Kane A., Yang I. Interferon-gamma in brain tumor immunotherapy. Neurosurg. Clin. N. Am. 2010, 21:77-86.
24. Kren L., Muckova K., Lzicarova E., Sova M., Vybihal V., Svoboda T., Fadrus P., Smrcka M., Slaby O., Lakomy R., Vanhara P., Krenova Z., Michalek J. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity?. J. Neuroimmunol. 2010, 220:131-135.
25. Kren L., Slaby O., Muckova K., Lzicarova E., Sova M., Vybihal V., Svoboda T., Fadrus P., Lakomy R., Vanhara P., Krenova Z., Sterba J., Smrcka M., Michalek J. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance?. Neuropathology 2011, 31:129-134.
26. Lee-MacAry A.E., Ross E.L., Davies D., Laylor R., Honeychurch J., Glennie M.J., Snary D., Wilkinson R.W. Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. J. Immunol. Methods 2001, 252:83-92.
27. Levy E.M., Bianchini M., Von Euw E.M., Barrio M.M., Bravo A.I., Furman D., Domenichini E., Macagno C., Pinsky V., Zucchini C., Valvassori L., Mordoh J. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int. J. Oncol. 2008, 32:633-641.
28. Malmberg K.J., Levitsky V., Norell H., de Matos C.T., Carlsten M., Schedvins K., Rabbani H., Moretta A., Soderstrom K., Levitskaya J., Kiessling R. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 2002, 110:1515-1523.
29. Marin R., Ruiz-Cabello F., Pedrinaci S., Mendez R., Jimenez P., Geraghty D.E., Garrido F. Analysis of HLA-E expression in human tumors. Immunogenetics 2003, 54:767-775.
30. Mittelbronn M., Simon P., Loffler C., Capper D., Bunz B., Harter P., Schlaszus H., Schleich A., Tabatabai G., Goeppert B., Meyermann R., Weller M., Wischhusen J. Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J. Neuroimmunol. 2007, 189:50-58.
31. Nguyen S., Beziat V., Dhedin N., Kuentz M., Vernant J.P., Debre P., Vieillard V. HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant. 2009, 43:693-699.
32. Palmisano G.L., Contardi E., Morabito A., Gargaglione V., Ferrara G.B., Pistillo M.P. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum. Immunol. 2005, 66:1-12.
33. Pietra G., Romagnani C., Mazzarino P., Falco M., Millo E., Moretta A., Moretta L., Mingari M.C. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10896-10901.
34. Pietra G., Romagnani C., Moretta L., Mingari M.C. HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells. Curr. Pharm. Des. 2009, 15:3336-3344.
35. Robertson M.J., Cochran K.J., Cameron C., Le J.M., Tantravahi R., Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 1996, 24:406-415.
36. Schulte D., Vogel M., Langhans B., Kramer B., Korner C., Nischalke H.D., Steinberg V., Michalk M., Berg T., Rockstroh J.K., Sauerbruch T., Spengler U., Nattermann J. The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. J. Infect. Dis. 2009, 200:1397-1401.
37. Sensi M., Pietra G., Molla A., Nicolini G., Vegetti C., Bersani I., Millo E., Weiss E., Moretta L., Mingari M.C., Anichini A. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. Int. Immunol. 2009, 21:257-268.
38. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
39. Tabatabai G., Weller M. Glioblastoma stem cells. Cell Tissue Res. 2011, 343:459-465.
40. Ulbrecht M., Couturier A., Martinozzi S., Pla M., Srivastava R., Peterson P.A., Weiss E.H. Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur. J. Immunol. 1999, 29:537-547.
41. Wada H., Matsumoto N., Maenaka K., Suzuki K., Yamamoto K. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur. J. Immunol. 2004, 34:81-90.
42. Wei J., Barr J., Kong L.Y., Wang Y., Wu A., Sharma A.K., Gumin J., Henry V., Colman H., Priebe W., Sawaya R., Lang F.F., Heimberger A.B. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol. Cancer Ther. 2010, 9:67-78.
43. Wei J., Barr J., Kong L.Y., Wang Y., Wu A., Sharma A.K., Gumin J., Henry V., Colman H., Sawaya R., Lang F.F., Heimberger A.B. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 2010, 16:461-473.
44. Wischhusen J., Friese M.A., Mittelbronn M., Meyermann R., Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J. Neuropathol. Exp. Neurol. 2005, 64:523-528.
45. Wischhusen J., Waschbisch A., Wiendl H. Immune-refractory cancers and their little helpers-an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. Semin. Cancer Biol. 2007, 17:459-468.